Qlucore AB (publ)
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more
Qlucore AB (publ) (NOVKAN) - Net Assets
Latest net assets as of December 2025: Skr15.06 Million SEK
Based on the latest financial reports, Qlucore AB (publ) (NOVKAN) has net assets worth Skr15.06 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr16.73 Million) and total liabilities (Skr1.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr15.06 Million |
| % of Total Assets | 90.03% |
| Annual Growth Rate | 2.08% |
| 5-Year Change | -87.71% |
| 10-Year Change | -74.69% |
| Growth Volatility | 116.47 |
Qlucore AB (publ) - Net Assets Trend (2010–2025)
This chart illustrates how Qlucore AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Qlucore AB (publ) (2010–2025)
The table below shows the annual net assets of Qlucore AB (publ) from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr15.06 Million | -75.82% |
| 2024-12-31 | Skr62.30 Million | +30.70% |
| 2023-12-31 | Skr47.66 Million | -55.42% |
| 2022-12-31 | Skr106.91 Million | -12.75% |
| 2021-12-31 | Skr122.54 Million | +69.52% |
| 2020-12-31 | Skr72.28 Million | +314.97% |
| 2019-12-31 | Skr17.42 Million | -47.78% |
| 2018-12-31 | Skr33.36 Million | -13.83% |
| 2017-12-31 | Skr38.71 Million | -34.97% |
| 2016-12-31 | Skr59.52 Million | +171.49% |
| 2015-12-31 | Skr21.93 Million | -19.66% |
| 2014-12-31 | Skr27.29 Million | +43.96% |
| 2013-12-31 | Skr18.96 Million | +244.72% |
| 2012-12-31 | Skr5.50 Million | -78.77% |
| 2011-12-31 | Skr25.90 Million | +134.01% |
| 2010-12-31 | Skr11.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Qlucore AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45553500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.78 Million | 78.18% |
| Other Components | Skr458.82 Million | 3045.62% |
| Total Equity | Skr15.06 Million | 100.00% |
Qlucore AB (publ) Competitors by Market Cap
The table below lists competitors of Qlucore AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ARK Resources Bhd
KLSE:7007
|
$1.08 Million |
|
KBC GR
BE:KDB
|
$1.08 Million |
|
LCK Global Kedaton
JK:LCKM
|
$1.08 Million |
|
WisdomTree Efficient Gold Plus Gold Miners Strategy Fund
BATS:GDMN
|
$1.08 Million |
|
KBC GR - Dusseldorf Stock Exchang
DU:KDB
|
$1.08 Million |
|
CORNING INC - Dusseldorf Stock Exchang
DU:GLW
|
$1.08 Million |
|
Altex Industries Inc
PINK:ALTX
|
$1.08 Million |
|
Wool Industry Tria Alfa S.A.
AT:AAAK
|
$1.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qlucore AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 62,300,000 to 15,065,000, a change of -47,235,000 (-75.8%).
- Net loss of 46,771,000 reduced equity.
- Other factors decreased equity by 464,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-46.77 Million | -310.46% |
| Other Changes | Skr-464.00K | -3.08% |
| Total Change | Skr- | -75.82% |
Book Value vs Market Value Analysis
This analysis compares Qlucore AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.89x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | Skr4.16 | Skr0.11 | x |
| 2011-12-31 | Skr8.89 | Skr0.11 | x |
| 2012-12-31 | Skr1.52 | Skr0.11 | x |
| 2013-12-31 | Skr3.69 | Skr0.11 | x |
| 2014-12-31 | Skr2.10 | Skr0.11 | x |
| 2015-12-31 | Skr1.50 | Skr0.11 | x |
| 2016-12-31 | Skr3.68 | Skr0.11 | x |
| 2017-12-31 | Skr2.13 | Skr0.11 | x |
| 2018-12-31 | Skr1.53 | Skr0.11 | x |
| 2019-12-31 | Skr0.68 | Skr0.11 | x |
| 2020-12-31 | Skr1.64 | Skr0.11 | x |
| 2021-12-31 | Skr1.83 | Skr0.11 | x |
| 2022-12-31 | Skr1.80 | Skr0.11 | x |
| 2023-12-31 | Skr0.60 | Skr0.11 | x |
| 2024-12-31 | Skr0.54 | Skr0.11 | x |
| 2025-12-31 | Skr0.12 | Skr0.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qlucore AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -310.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-310.46%) is below the historical average (-132.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -64.57% | 0.00% | 0.00x | 1.27x | Skr-8.25 Million |
| 2011 | -71.07% | -260.43% | 0.18x | 1.53x | Skr-21.00 Million |
| 2012 | -608.98% | -872.31% | 0.21x | 3.40x | Skr-34.04 Million |
| 2013 | -39.13% | -409.16% | 0.07x | 1.35x | Skr-9.31 Million |
| 2014 | -58.55% | -3399.79% | 0.01x | 1.33x | Skr-18.71 Million |
| 2015 | -89.45% | -6954.61% | 0.01x | 1.25x | Skr-21.80 Million |
| 2016 | -37.48% | -7242.86% | 0.00x | 1.23x | Skr-28.26 Million |
| 2017 | -145.17% | -49732.74% | 0.00x | 1.32x | Skr-60.07 Million |
| 2018 | -137.71% | -12831.01% | 0.01x | 1.37x | Skr-49.27 Million |
| 2019 | -207.22% | -1122.36% | 0.07x | 2.55x | Skr-37.84 Million |
| 2020 | -56.03% | -45000.00% | 0.00x | 1.15x | Skr-47.73 Million |
| 2021 | -37.28% | -2681.10% | 0.01x | 1.09x | Skr-57.94 Million |
| 2022 | -49.09% | -6969.99% | 0.01x | 1.13x | Skr-63.18 Million |
| 2023 | -136.14% | -6269.47% | 0.02x | 1.38x | Skr-69.66 Million |
| 2024 | -71.53% | -318328.57% | 0.00x | 1.07x | Skr-50.80 Million |
| 2025 | -310.46% | 0.00% | 0.00x | 1.11x | Skr-48.28 Million |
Industry Comparison
This section compares Qlucore AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qlucore AB (publ) (NOVKAN) | Skr15.06 Million | -64.57% | 0.11x | $1.08 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |